Matches in Nanopublications for { ?s ?p ""Fenofibric acid delayed-release capsules are contraindicated in: patients with severe renal impairment, including those receiving dialysis [see Clinical Pharmacology ( 12.3 patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Warnings and Precautions ( 5.3 patients with preexisting gallbladder disease [see Warnings and Precautions ( 5.5 nursing mothers [see Use in Specific Populations ( 8.2 patients with hypersensitivity to fenofibric acid or fenofibrate [see Warnings and Precautions ( 5.9 Severe renal dysfunction, including patients receiving dialysis ( 4 , 12.3 ). Active liver disease ( 4 , 5.3 ). Gallbladder disease ( 4 , 5.5 ). Lactation ( 4 , 8.2 ). Known hypersensitivity to fenofibric acid or fenofibrate ( 4 , 5.9 )."" ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- association label ""Fenofibric acid delayed-release capsules are contraindicated in: patients with severe renal impairment, including those receiving dialysis [see Clinical Pharmacology ( 12.3 patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Warnings and Precautions ( 5.3 patients with preexisting gallbladder disease [see Warnings and Precautions ( 5.5 nursing mothers [see Use in Specific Populations ( 8.2 patients with hypersensitivity to fenofibric acid or fenofibrate [see Warnings and Precautions ( 5.9 Severe renal dysfunction, including patients receiving dialysis ( 4 , 12.3 ). Active liver disease ( 4 , 5.3 ). Gallbladder disease ( 4 , 5.5 ). Lactation ( 4 , 8.2 ). Known hypersensitivity to fenofibric acid or fenofibrate ( 4 , 5.9 )."" assertion.